biontech investor relations

Former U.S. Secretary of Agriculture. Eide Bailly, LLP Bion is a technology and policy leader in this new ‘space’ that is developing at the intersection of the $200B animal-protein industry and the $100B clean water sector. For the most part, the industry has been unable to relocate or consolidate to mitigate these effects because of the environmental impacts of production. The opportunity is to clean up livestock production, the ‘dirtiest’ part of the food supply chain…and the largest unregulated source of pollution in the U.S. Bion Announces Core Optimization Trials Complete, Shareholder Alert – Bion Enters USEPA-USDA Next Gen Fertilizer Challenge, Bion Announces New U.S. Patent Provides Stronger Coverage of Third-Gen Technology. An increasing circle of stakeholders understand this need, as well: federal and state policies are evolving to encourage and support/ fund livestock waste cleanup. Bion’s verified results will back both a USDA-certified sustainable brand that will regain and hold the confidence and trust of its consumers, as well as water quality improvements that will save taxpayers billions of dollars. Bion’s platform also provides dramatic reductions of greenhouse gas, ammonia and hydrogen sulfide emissions, as well as pathogens in the waste stream that have been linked to foodborne illnesses and antibiotic resistance. Germany, For questions on logistics, The Investor Relations website contains information about BioNTech's business for stockholders, potential investors, and financial analysts. Bion’s direct treatment of livestock waste can provide large-scale verifiable nutrient reductions at significantly lower cost than current agricultural and downstream treatment strategies. All documents on this website speak as of their date and the Company undertakes no obligation to publicly update or revise any forward-looking statements they may contain. BioNTech’s Investor Relations Sylke Maas, Ph.D. VP Investor Relations & Business Strategy Tel: +49 (0)6131 9084 1074 E-mail: Investors@biontech.de. Investor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074 Investors@biontech.de. use our contact form atconnect.biontech.de, We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases, Our vision: individualize cancer medicine, How we approach individualized cancer medicine, Why mRNA represents a disruptive new drug class, Beyond mRNA: Expanding therapeutics with our antibody discovery engines, Explore our individualized immunotherapy pipeline, Tour our platforms that produce individually-tailored therapeutics, Our Mission: broaden the therapeutic universe to benefit patients. BioNTech’s Media Relations Jasmina Alatovic Senior Manager Global External Communications Tel: +49 (0)6131 9084 1513 or +49 (0)151 1978 1385 E-mail: Media@biontech.de. Pfizer Media Relations Amy Rose (U.S.) BioNTech: Media Relations Jasmina Alatovic +49 (0)6131 9084 1513 Media@biontech.de. Pfizer-BioNTech vaccine can produce antibodies, immune cells 12 days after first dose: S'pore study Nation 22h ago Khairy: 585 vials of Pfizer's Covid-19 … Legislation to establish a competitively-bid procurement program in Pennsylvania, which will allow Bion and other private-sector providers to sell low-cost nutrient credits to the state, was introduced in the PA Senate in June 2017; in February 2018, the bill passed in the Senate 47-2, but was not considered in the House. Bion’s technology platform provides low-cost high-impact solutions to the industry’s environmental and public health issues AND delivers substantially better efficiencies and economics simultaneously. They spread it on the ground, untreated, for it’s fertilizer value. BioNTech SE An der Goldgrube 12 55131 Mainz Germany. Bion expects a competitive procurement program to be implemented in Pennsylvania in 2018. Pilot studies indicate that under certain conditions and locations, more fully described in the current Company Overview and SEC filings, projects can be developed that can be supported by coproduct and renewable energy production alone. Investor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074 BioNTech Media Relations Jasmina Alatovic Senior Manager Global External Communications Tel: +49 (0)6131 9084 7640 or +49 (0)151 1978 1385 E-mail: media@biontech.de BioNTech Investor Relations Sylke Maas, Ph.D. VP Investor Relations & Business Strategy Tel: +49 (0)6131 9084 1074 E-mail: Investors@biontech.de. Many of us here in Pennsylvania have taken our role as protectors of our land, our environment and the Chesapeake Bay very seriously and that’s why our partnership with Bion made sense from day one. Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech Contacts: Media Relations Jasmina Alatovic +49 (0)6131 9084 1513 or +49 (0)151 1978 1385 Media@biontech.de. The Director/Senior Director, Capital Markets & Investor Relations will be responsible for ensuring BioNTech is strategically positioned with external stakeholders in the US. Corporate Stock Transfer BioNTech is funded by 16 investors. BioNTech: Media Relations Jasmina Alatovic +49 (0)6131 9084 1513 Media@biontech.de. Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evalu.. March 15, 2021 from 5:00 PM to 6:00 PM EDT. Pfizer Investor Relations Chuck Triano +1 (212) 733-3901 Charles.E.Triano@Pfizer.com. Bion’s technology provides a ‘cleantech makeover’ for large-scale livestock production, with dramatic reductions in environmental impacts and significant improvements to resource and operational efficiencies. Perhaps the greatest value Bion’s technology brings, is that the verification of the environmental benefits also forms the basis for a sustainable brand that will communicate the steps taken to reduce environmental impacts to the consumer. The industry is under attack for these impacts from a wide range of detractors and competitors and they are losing customers at an alarming rate. Ultimately, the greatest ‘driver’ for Bion may be America’s and the world’s buying habits, that are undergoing a fundamental shift. BioNTech SE 303.770.5700, Transfer Agent The bill was approved in the Senate in a bipartisan vote and is now in the House State Government Committee. Investor Relations Chuck Triano +1 (212) 733-3901 Charles.E.Triano@Pfizer.com. Bion Environmental Technologies’ (OTC QB: BNET) patented and proven technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities – dairy, meat and egg producers. Because land is no longer required to spread waste on, divesting acreage or expansion on existing acreage can be considered. Investor Relations Chuck Triano +1 (212) 733-3901 Charles.E.Triano@Pfizer.com. Investor Relations Chuck Triano +1 (212) 733-3901 Charles.E.Triano@Pfizer.com. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Data Provided by Refinitiv. Investors in BioNTech SE (Symbol: BNTX) saw new options become available today, for the April 30th expiration. Media Relations Amy Rose +1 (212) 733-1226 PfizerMediaRelations@pfizer.com Investor Relations Chuck Triano +1 (212) 733-3901 Charles.E.Triano@Pfizer.com BioNTech: Media Relations Jasmina Alatovic +49 89 62 81 75 46 Media@biontech.de Investor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074 Investors@biontech.de. Market Makers. Michelle Vigil, public relations manager, told CNN on Tuesday that San Antonio is "currently operating at a 25% occupancy and will require masks for … T: +49 6131 9084-0 For questions on logistics, handling or other issues: service@biontech.de For any other questions, please use our contact form at connect.biontech.de. Companies on the cutting edge of these efforts, like Bion, can change the entire way that farming and natural resource management have been done throughout our history. One of Germany’s wealthiest software tycoons is the biggest shareholder in CureVac, a company racing to develop a coronavirus vaccine. Sylke Maas-- Vice President, Investor Relations, and business Strategy Thank you for joining us today for BioNTech's fourth quarter and full-year 2019 update call. handling or other issues:service@biontech.de, For any other questions, please Investor Relations: Sylke Maas, Ph.D., VP Investor Relations & Business Strategy Tel: +49 (0)6131 9084 1074 E-mail: Investors@biontech.de. BioNTech Contacts: Media Relations Jasmina Alatovic +49 (0) 6131 9084 1513 Media@biontech.de. Documents on this website contain forward-looking statements based on management’s current reasonable business expectations. BioNTech Media Relations Jasmina Alatovic +49 (0)6131 9084 1513 or +49 (0)151 1978 1385 Media@biontech.de. Cleanup is inevitable, but complicated; the industry is not regulated under the Clean Water Act and its margins are thin – the money is just not there. At Stock Options Channel, our YieldBoost … cleaner water…cleaner air…better economics. Bion’s business model, coupled with the policy change it supports, provides the industry a pathway to sustainability, without bankrupting it. German Federal Ministry of Education and Research (BMBF) and Temasek Holdings are the most recent investors. Global Media Relations Contact Sharon Castillo +1 202.624.6769 Sharon.Castillo@Pfizer.com. Legislation to apply the federal energy tax credit to nutrient recovery was recently introduced in the U.S. House and Senate and enjoys bipartisan support. The livestock industry has struggled for the last decade to deal with rising fuel costs and drought conditions that have exposed critical weaknesses in its supply chain. Companies on the cutting edge of these efforts, like Bion, can change the entire way that farming and natural resource management have been done throughout our history. Bion is a recognized leader in both technology and policy development in this transformation and stands to be a central player as it unfolds. The announcement stated, “EPA efforts seek to modernize the agency’s water quality trading policies to leverage emerging technologies and facilitate broader adoption of market-based programs.”. Their stock opened with $15.00 in its Oct 9, 2019 IPO. We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. 3200 Cherry Creek Dr. South, Ste 430 Investor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074 Investors@biontech.de BioNTech Media Relations Jasmina Alatovic Senior Manager Global External Communications Tel: +49 (0)6131 9084 7640 or +49 (0)151 1978 1385 E-mail: Media@biontech.de. Further, the industry has now recognized that it will need to verify and communicate this improved sustainability to the consumer. Bion Environmental Technologies, Inc., is publicly-traded on the OTC Markets QB: BNET. Bion’s technology platform creates value from the waste stream in several ways. Investor Relations Chuck Triano +1 (212) 733-3901 Charles.E.Triano@Pfizer.com. The Director/Senior Director, Capital Markets & Investor Relations will be responsible for ensuring BioNTech is strategically positioned with external stakeholders in the US. Investor Relations Sylke Maas, Ph.D.VP Investor Relations & Business StrategyTel: +49 (0)6131 9084 1074E-mail: Investors@biontech.de. Excess nutrients – nitrogen and phosphorus – cause toxic algal blooms and dead zones that the EPA now calls the greatest water quality problem in the U.S. today. BioNTech Contacts: Media Relations Jasmina Alatovic +49 6131 9084-0 Media@biontech.de. CEO and president, Kreider Farms, Auditor While the policy changes we support are still a major focus of our business, we are no longer entirely dependent on them. Since late in 2018, the US EPA and USDA have signaled several times that they support market-driven strategies, such as ‘reverse auctions’ (competitive procurement) and trading. And Bion’s expertise, coupled with its technology solutions that have been proven over many years, place it far ahead of future competitors in this evolving space. Investor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074 Investors@biontech.de Contacts Pfizer: Media Relations Amy Rose +1 (212) 733-7410 Amy.Rose@pfizer.com Production agriculture, environmental necessities and raw economics are coming together like never before. The industry is ready to be engaged and supports these changes. Minimum 15 minutes delayed. The U.S. livestock industry must reduce its footprint and simultaneously improve its efficiencies if it is to remain environmentally and economically sustainable in the modern world. 55131 Mainz National livestock interests, including National Milk Producers Federation, Land O’Lakes, Dairy Farmers of America, JBS (the largest beef/pork producer in the world), Pennsylvania Farm Bureau, and others have recently joined Bion in support of such a strategy. Verifying the removal of these coproducts (formerly pollutants) from the waste stream produces additional revenues from the sale of renewable energy and carbon credits, as well as nutrient credits described below. An unintended consequence of siting large-scale facilities in out-of-the-way locations has been a significant increase in transportation costs and impacts. Ceres and other large activist institutional investors have already expressed concerns about carbon footprint, water quality, antibiotic usage and animal welfare to many in the food production industry. These credits, coupled with the pipeline-quality natural gas, high-value fertilizer, and feed products, represent the recurring revenues needed to offset technology adoption costs. Pfizer Media Relations Amy Rose (U.S.) Water is treated sufficiently (including pathogen kill) for re-use by the herd, irrigation or aquifer recharge. Symbol In a recent Letter of Expectation (click for highlighted version), US EPA made it clear to Pennsylvania that the agency supports and encourages the use of credit trading, competitive procurement and other market-driven strategies to comply with the Commonwealth’s Bay mandates. While policy change is taking place, recent improvements to Bion’s technology platform – our recently patented Third Generation (3G) technology platform – will enable the recovery of much higher-value coproducts and renewable energy than previous generations. Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vac.. Pfizer-BioNTech’s COVID-19 Vaccine Arrives in Rwanda. SB575, the bill’s successor was introduced in the Senate in June 2019 and is strongly supported by a PA legislative leadership on both sides of the aisle. BioNTech Contacts: Media Relations Jasmina Alatovic +49 6131 9084-0 Media@biontech.de. Investor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074 Investors@biontech.de The bottom line is that Bion can provide verified nitrogen reductions at $10 to $12 per pound per year, at scale, where the state is facing costs starting at $30 per pound and climbing into the hundreds. BioNTech Media Relations Jasmina Alatovic Senior Manager Global External Communications Tel: +49 (0)6131 9084 7640 or +49 (0)151 1978 1385 E-mail: media@biontech.de. 303.282.4800. Whole Foods, Walmart, Costco, McDonalds, and most other large meat and dairy product retailers have recently announced sustainability initiatives. Bion’s technology addresses both of these inescapable challenges that will require significant investment over the coming years. Pfizer Media Relations Related Quotes. In This Story BNTX. Pfizer Media Relations Amy Rose +1 (212) 733-7410 Amy.Rose@Pfizer.com. Environmentally Sustainable Livestock Production. Investor Relations Chuck Triano +1 (212) 733-3901 Charles.E.Triano@Pfizer.com. Media Relations Amy Rose +1 (212) 733-1226 PfizerMediaRelations@pfizer.com. E-mail: Media@biontech.de. Greenhouse gas, ammonia, hydrogen sulfide and odor emissions are dramatically reduced. Some of the largest national producers in the livestock industry are at the table with Bion, ready and willing to be engaged. Source: Pfizer Inc. Media Relations Jerica Pitts +1 (212) 733-1226 Jerica.Pitts@pfizer.com Investor Relations Chuck Triano +1 (212) 733-3901 Charles.E.Triano@Pfizer.com BioNTech Contacts: Media Relations Jasmina Alatovic +49 (0)6131 9084 1513 or +49 (0)151 1978 1385 Media@biontech.de Investor Relations Sylke Maas, Ph.D. +49 (0)6131 9084 1074 Investors@biontech.de Investors. Bion’s technology platform enables clean state-of-the-art livestock facilities to be developed in new strategic locations that substantially reduce logistics costs, improve economics and reduce carbon footprint.

Pfizer Ex Dividende 2021, Alfons Haider Partner, Metzgerei Friedrich Sülzburgstraße, Hausschlachtung 2020 Bayern, Formel 1 2006 Ergebnisse, Mörderische Spiele Staffel 4, Wetter Zandvoort Morgen, Westfleisch Coesfeld Adresse,